Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.67 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111738 | 0.90 | NAMPT (0.56) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL22564659 | 0.88 | GPR119 (0.67) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL226854 | 0.88 | NAMPT (0.59) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL229512 | 0.86 | NAMPT (0.58) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL570083 | 0.86 | GPR119 (0.56) | GPR119NAMPTKDM4EKMT2ACYP2C9 | |
| SCHEMBL270733 | 0.86 | NAMPT (0.60) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL1199259 | 0.86 | NAMPT (0.57) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL1198897 | 0.85 | NAMPT (0.60) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL8251243 | 0.85 | NAMPT (0.57) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL28852640 | 0.85 | NAMPT (0.52) | GPR119NAMPTKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024197289-A1 | NEGATIVE ALLOSTERIC MODULATORS OF GLUN2B RECEPTORS AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| EP-3418277-B1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-10-14 | — | — | EP | disclosed |
| US-20200172510-A1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-04 | — | — | US | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | GPR119 658/4885NAMPT 1769/4885PARP10 3078/4885 |
| US-20200172510-A1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | NOS2, NOS1, NOS3 | GPR119 397/4885NAMPT 1048/4885PARP10 2696/4885 |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | NOS2, NOS1, NOS3 | GPR119 427/4885NAMPT 1144/4885PARP10 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.